Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 24, Issue 10, Pages 2876-2880Publisher
SPRINGER
DOI: 10.1245/s10434-017-5961-9
Keywords
-
Funding
- Innocrin
- Pfizer/Medivation
- Astellas
Ask authors/readers for more resources
A growing body of literature supports the conclusion that the androgen receptor (AR) plays an important role in breast cancer pathogenesis and may prove to be a relevant therapeutic target for patients with AR-driven breast cancer. This has been most apparent in the subset of patients with triple-negative breast cancer (TNBC), in whom approximately 50% of tumors may have androgen dependence. Recent phase 2 clinical trials of agents that antagonize AR or reduce androgen production have shown clinical benefit and efficacy to varying degrees. This review highlights three of these recent trials of AR(+) TNBC and acknowledge ongoing research in this exciting area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available